Leerink Partnrs Reduces Earnings Estimates for ICON Public

ICON Public Limited (NASDAQ:ICLR) – Research analysts at Leerink Partnrs dropped their FY2025 EPS estimates for ICON Public in a research note issued to investors on Monday, January 6th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $13.98 per share for the year, down from their prior forecast of $14.11. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.81 EPS and FY2027 earnings at $17.82 EPS.

A number of other equities research analysts also recently issued reports on ICLR. Robert W. Baird cut their target price on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. Barclays dropped their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Citigroup decreased their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research note on Monday. Royal Bank of Canada initiated coverage on shares of ICON Public in a report on Tuesday. They set an “outperform” rating and a $263.00 price objective on the stock. Finally, Baird R W lowered shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.00.

ICON Public Price Performance

ICLR stock opened at $219.34 on Wednesday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $18.09 billion, a PE ratio of 24.45, a P/E/G ratio of 1.54 and a beta of 1.20. ICON Public has a one year low of $183.38 and a one year high of $347.72. The firm has a 50-day moving average of $211.37 and a two-hundred day moving average of $272.75.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. ICON Public’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the company posted $3.10 EPS.

Institutional Investors Weigh In On ICON Public

Institutional investors and hedge funds have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of ICON Public during the 2nd quarter valued at $54,000. EverSource Wealth Advisors LLC lifted its stake in ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 111 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of ICON Public by 23.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.